Discovery of novel Macrocyclic small molecules Based on 2-Amino-4-thiazolylpyridineas selective EGFR inhibitors with high Blood-Brain barrier penetration for the treatment of glioblastoma
- 23 October 2024
- journal article
- research article
- Published by Elsevier in Bioorganic Chemistry
- Vol. 153, 107905
Abstract
No abstract availableKeywords
Funding Information
- Guangzhou Municipal Science and Technology Bureau
- Basic and Applied Basic Research Foundation of Guangdong Province (2023A1515011038)
- Natural Science Foundation of Guangdong Province (2021A1515011246)
This publication has 31 references indexed in Scilit:
- Improving the efficacy of anti-EGFR drugs in GBM: Where we are going?Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2023
- 20 years since the approval of first EGFR-TKI, gefitinib: Insight and foresightBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2023
- Challenge and countermeasures for EGFR targeted therapy in non-small cell lung cancerBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2022
- Computational studies of potent covalent inhibitors on wild type or T790M/L858R mutant epidermal growth factor receptorEuropean Journal of Pharmaceutical Sciences, 2020
- Trends in glioblastoma: outcomes over time and type of intervention: a systematic evidence based analysisJournal of Neuro-Oncology, 2020
- Design, synthesis and biological evaluation of 2-amino-4-(1,2,4-triazol)pyridine derivatives as potent EGFR inhibitors to overcome TKI-resistanceEuropean Journal of Medicinal Chemistry, 2020
- The Effect of Rifampin on the Pharmacokinetics and Safety of Lorlatinib: Results of a Phase One, Open-Label, Crossover Study in Healthy ParticipantsAdvances in Therapy, 2019
- Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With GlioblastomaJAMA, 2017
- Nitrosoureas in the Management of Malignant GliomasCurrent Neurology and Neuroscience Reports, 2016
- The Somatic Genomic Landscape of GlioblastomaCell, 2013